Roche vs. ABL Bio: Bispecific Antibody BBB Shuttle Platform Performance Update
What is the current status of the ‘Roche/ABL Bio’ bispecific antibody BBB shuttle platform performance? [이데일리 김진호 기자] Roche of Switzerland is leading the development of a new dual antibody drug for Alzheimer’s using a brain delivery platform. The company is trying again with the bispecific antibody ‘Trontinemab’, which increased the delivery rate to the … Read more